The Southwest Oncology Group has used adriamycin alone and in combination with other agents in the treatment of Hodgkin's disease and non Hodgkin's lymphoma. When a single 75 mg/m2 dose was given every 3 weeks, the complete plus partial response rate was 39% in patients with Hodgkin's disease and 44% in those with nonHodgkin's lymphoma. These patients had had extensive prior chemotherapy. An adriamycin dose response study subsequently compared the single dose of 75 mg/m2 with that of 45mg/m2 given every 3 weeks. There is some evidence of a dose response relationship in nonHodgkin's lymphoma (45% vs 29% response rate). Adriamycin was added to cyclophosphamide, vincristine, and prednisone (CHOP) and was compared with adriamycin, vincristine, and prednisone (HOP) in the treatment of patients with advanced non Hodgkin's lymphoma. The complete response rate was 55% for CHOP and 50% for HOP. The toxicity of these two regimens was marked. The durations of complete response were no different in the two limbs, and the Kaplan and Meier estimate of the 2 year disease free interval is 75% for CHOP and 60% for HOP. A pilot study was done to test the feasibility of adding adriamycin to the best prior regimen used in advanced Hodgkin's disease, which was mechlorethamine, vincristine, prednisone, and procarbazine (MOPP) plus low dose bleomycin. Two schedules were tested: 30mg/m2 of adriamycin was given in place of mechlorethamine on Day 8 of each of ten cycles of MOPP plus low dose bleomycin; and 15 mg/m2 of adriamycin added on Days 1 and 8 of each of ten MOPP plus low dose bleomycin cycles with an attenuated dose (3mg/m2) of mechlorethamine on Days 1 and 8. These well tolerated regimens are now being compared to MOPP plus low dose bleomycin in advanced Hodgkin's disease in a group wide study.
|Original language||English (US)|
|Number of pages||6|
|State||Published - 1975|
ASJC Scopus subject areas